Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
University of Cologne · Düsseldorf University Hospital · +28 more institutions
Abstract
The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known.
In this open-label, phase 3 trial, we investigated fixed-duration treatment with venetoclax and obinutuzumab in patients with previously untreated CLL and coexisting conditions. Patients with a score of greater than 6 on the Cumulative Illness Rating Scale (scores range from 0 to 56, with higher scores indicating more impaired function of organ systems) or a calculated creatinine clearance of less than 70 ml per minute were randomly assigned to receive venetoclax-obinutuzumab or chlorambucil-obinutuzumab. The primary end point was investigator-assessed progression-free survival. The safety of each regimen was also evaluated.
Citation impact
- FWCI
- 71.39
- Percentile
- 100%
- References
- 33
Authors
32- KFKirsten FischerCorresponding
University of Cologne, Düsseldorf University Hospital, Integrated Oncology (United States), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Heinrich Heine University Düsseldorf
- OAOthman Al‐Sawaf
University of Cologne, Düsseldorf University Hospital, Integrated Oncology (United States), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Heinrich Heine University Düsseldorf
- JBJasmin Bahlo
University of Cologne, Düsseldorf University Hospital, Integrated Oncology (United States), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Heinrich Heine University Düsseldorf
- AFAnna‐Maria Fink
University of Cologne, Düsseldorf University Hospital, Integrated Oncology (United States), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Heinrich Heine University Düsseldorf
- MTManeesh Tandon
Düsseldorf University Hospital, Roche (United Kingdom), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Heinrich Heine University Düsseldorf
Topics & keywords
- Venetoclax
- Obinutuzumab
- Medicine
- Ibrutinib
- Internal medicine
- Oncology
- Cancer research
- Chronic lymphocytic leukemia
- Zero hunger